Portola – A High-Risk, High-Return Investment Opportunity

  • Portola Pharmaceuticals is looking to launch BevyxXa, the first and only once-daily oral anticoagulant indicated for extended prophylaxis of venous thromboembolism in acutely ill medical patients at high risk.
  • The company also awaits CHMP decisions on BevyxXa and AndexXa.
  • The company stock is currently down 18% from its 52-week high, offering an attractive entry point.

By S. Mitra, MBA (ISB)

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) received another positive impetus for its stock price when the company reported that its resubmitted Biologics License Application (BLA) for AndexXa® has been found acceptable by the FDA for review. AndexXa is being developed as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled or life-threatening bleeding event or who require urgent or emergency surgery.

The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.

An abridged version is available below to our investor members. Login or Subscribe here.